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ABSTRACT
Background: Non-alcoholic fatty liver disease (NAFLD) is a liver disorder commonly found in the majority 
of patients with metabolic risk factors, such as obesity and type 2 diabetes. Apolipoprotein B (apoB) is the moiety 
of low density lipoprotein (LDL) and clinical interest that provides a relative accurate estimation of circulating 
LDL particle. The aim of this study was to know the relationship between apoB level and occurrence of fatty 
liver in type 2 diabetes mellitus (DM) with metabolic syndrome.
Method: A cross sectional study was conducted in patients suffered from type 2 DM with metabolic syndrome 
at Internal Medicine Outpatient Clinic in Moewardi Hospital Surakarta between April and May 2011. Thirty 
two patients with type 2 DM and metabolic syndrome were enrolled to this study and categorized into two 
groups; consisting of 16 patients with fatty liver and 16 patients without fatty liver. Student t-test was used in 
the analysis of this study. 
Results: Of 32 patients who fulfilled this study criteria, patients type 2 diabetes mellitus and metabolic 
syndrome with non-alcoholic fatty liver diseases (NAFLD) had higher apoB level than patients type 2 diabetes 
mellitus and metabolic syndrome without NAFLD (p = 0.013).
Conclusion: NAFLD group had significantly higher apoB level than without NAFLD group in type 2 DM 
with metabolic syndrome patients.
Keywords: apolipoprotein B, non-alcoholic fatty liver disease, type 2 DM, metabolic syndrome
ABSTRAK
Latar belakang: Perlemakan hati non alkoholik merupakan penyakit hati yang sering terjadi pada sebagian 
besar dari pasien yang mempunyai faktor risiko metabolik seperti obesitas dan diabetes tipe 2. Apolipoprotein 
B (ApoB) adalah bagian dari lipoprotein berdensitas rendah dan secara klinis dapat memperkirakan akurasi 
relatif dari sirkulasi partikel lipoprotein densitas rendah. Penelitian ini bertujuan untuk mengetahui hubungan 
antara kadar apolipoprotein B dengan terjadinya perlemakan hati pada pasien diabetes mellitus (DM) tipe 2 
dengan sindroma metabolik.
Metode: Desain penelitian potong lintang dilakukan pada 32 pasien rawat jalan bagian Penyakit Dalam 
Rumah Sakit Moewardi Surakarta pada bulan April-Mei 2011 yang menderita penyakit DM tipe 2 dengan 
sindroma metabolik. Total pasien tersebut dikatagorikan menjadi 2 kelompok, yaitu 16 pasien dengan perlemakan 
hati dan 16 pasien tanpa perlemakan hati. Penelitian ini dianalisis dengan menggunakan student t-test.
Hasil: Dari 32 pasien yang memenuhi kriteria penelitian, pasien DM tipe 2 dan sindroma metabolik dengan 
perlemakan hati mempunyai kadar apoB lebih tinggi dibandingkan pasien DM tipe 2 dan sindroma metabolik 
tanpa perlemakan hati (p < 0,013).
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Kesimpulan: Kelompok perlemakan hati memiliki kadar apolipoprotein B (apoB) yang signifikan lebih tinggi 
dari kelompok bukan perlemakan hati pada tipe 2 dengan sindroma metabolik. 
Kata kunci: apolipoprotein B, perlemakan hati non-alkoholik, DM tipe 2, sindroma metabolik
INTRODUCTION
Non-alcoholic fatty liver disease (NAFLD) is 
a common liver disorder, frequently identified in 
individuals who have absence of significant alcohol 
consumption. Although a number of circumstances 
have been implicated as risk factors, obesity is 
clearly the principal risk factor in the development 
of NAFLD.1 The prevalence of NAFLD in the 
general population is up to 30%; however, this is 
strongly associated with obesity, insulin resistance, 
hypertension and dyslipidemia and is now regarded as 
the liver manifestation of the metabolic syndrome.2,3
Lipid accumulation in the liver is the major hallmark 
of  NAFLD. Fatty liver-associated dyslipidemia profile 
characterized by large very low density lipoprotein 
(VLDL), small dense low density lipoprotein (LDL), 
and decreased large high density lipoprotein (HDL) 
correlates with intrahepatic lipid content.4
Apolipoproteins are important structural and 
functional proteins in lipoprotein particles, which 
transport lipids. Plasma apolipoprotein B has recently 
been closely associated with metabolic syndrome. 
Apolipoprotein B (ApoB) is the primary apolipoprotein 
of LDL-c, which is responsible for carrying cholesterol 
to tissues. ApoB measurement has many advantages. 
It does not require any fasting blood sample. It is a 
direct measurement. This means that there is no need 
for calculation from multiple parameters, which may 
introduce errors.5,6 The aim of this study was to know 
the correlation between apoB level and occurrence of 
fatty liver in type 2 diabetes mellitus with metabolic 
syndrome.
METHOD
A cross sectional study was conducted in 32 
patients suffered from type 2 DM with metabolic 
syndrome between April and May 2011, using data 
from an Internal Medicine Outpatient Clinic in 
Moewardi Hospital, Surakarta. A total of 32 patients 
were recruited and, categorized into two groups, 
consisting of 16 patients with NAFLD and 16 patients 
without NAFLD. Diagnosis of diabetes mellitus was 
made according to Consensus of Management and 
Prevention of Type 2 Diabetes Mellitus Indonesia 
2006 including:7 physical examination, laboratory 
findings, and medications. Metabolic syndrome was 
defined based on the criteria provided by the ATP III. 
The exclusion criteria were patients who had previous 
history of chronic liver disease, positive hepatitis viral 
sero-marker, or history of alcohol consumption.
The blood pressure was measured on the right arm 
using sphygmomanometer. Hypertension was defined 
as systolic blood pressure > 140 mmHg and/or diastolic 
blood pressure > 90 mmHg, or was considered to be 
present if patient had been treated with antihypertensive 
drugs before. Fasting blood sugar was measured after 
8 hours fasting, followed by measurements of high 
density lipoprotein cholesterol and, triglycerides. ApoB 
is measured by immunoturbidimetric method from dr. 
Moewardi Hospital laboratory.
Ultrasonographic examination of the liver was 
performed to detect fatty change in the liver. Described 
as hepatic fat is increased echogenicity on ultrasound, 
compared with the lower echogenicity of the spleen or 
renal cortex (bright liver). Data analysis was performed 
using student t-test with SPSS program. 
RESULTS
Of 32 total patients, 17 (54%) were female and all of 
them had type 2 DM and we continued the study with 
variables of metabolic syndrome. The characteristics 
were age, sex, type 2 DM, and metabolic syndrome 
criteria (ATP III criteria). The clinical characteristics 
of patients were detailed in Table 1.
Table 1. Patients’ characteristic
Characteristic n (%)
Mean of age (years)
Sex
Male
Female
Type 2 diabetes mellitus
Metabolic syndrome criteria
Central obesity (waist circumference)
Hypertriglyseride
Low HDL-C 
Hypertension
Elevated fasting plasma glucose
56.6
15 (46%)
17 (54%)
32 (100%)
24 (75%)
18 (56%)
23 (71%)
20 (62%)
18 (56%)
Apolipoprotein B (mean ± SD) 
Fatty liver (+) 
Fatty liver (-) 
 
111.7 ± 26
169.6 ± 79
HDL: high density lipoprotein; SD: standard deviation
ApoB level were significantly higher in type 2 DM 
and metabolic syndrome patients with fatty liver than 
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in type 2 DM and metabolic syndrome patients without 
fatty liver (p < 0.013), as seen in Figure 1.
reflected the number of small, dense LDL particles in 
plasma, was a significant predictor of cardiometabolic 
risk among adults with a high prevalence of metabolic 
syndrome.6
In this study we compared apoB level in type 2 
DM and metabolic syndrome patients with or without 
NAFLD. The results of this study revealed that the 
level of apoB was significantly higher in type 2 DM 
and metabolic syndrome patients with NAFLD than in 
type 2 DM and metabolic syndrome patients without 
NAFLD. These results suggested that apoB could be 
used as an alternative risk marker in type 2 DM and 
metabolic syndrome patients for NAFLD. However, we 
considered the possibility that the sample analyzed in 
this study was not representative. Further investigative 
studies with bigger sample size are need in the future.
CONCLUSION
Type 2 diabetes mellitus and metabolic syndrome 
in patients with NAFLD has higher apob level than 
type 2 diabetes mellitus and metabolic syndrome in 
patients without NAFLD.
REFERENCES
1. Seung HP, Byung IK, Sang HK, Hong JK, Dong IP, Yong 
KC, et al. Body fat distribution and insulin resistance: beyond 
obesity in non-alcoholic fatty liver disease among overweight 
men. J Am Coll Nutr 2007;4:321–6.
2. Nimantha MW, Christopher PD. Non-alcoholic fatty liver 
disease: the mist gradually clears. J Hepatol 2008;48:104–12.
3. Mireille A, Folkert K, Ronald P. Non-alcoholic fatty liver 
disease is associated with cardiovascular disease risk markers. 
Obes Rev 2009;10:412-9.
4. Klementina FT, Damjana R. Non-alcoholic fatty liver disease: 
focus on lipoprotein and lipid deregulation. Hindawi J Lipids 
2011;2011:1-14.
5. Nattapol S, Apussanee B. Apolipoprotein B level in patients 
with type 2 diabetes who achieved goal of low density 
lipoprotein cholesterol and non-high density lipoprotein 
cholesterol. J Med Assoc Thai 2010;93:166-72.
6. Onat A, Can G, Hergen G, Yazıcı M, Karabulut A, Albayrak 
S. Serum apolipoprotein B predicts dyslipidemia, metabolic 
syndrome and, in women, hypertension and diabetes, 
independent of markers of central obesity and inflammation. 
Int J Obes 2007;31:1119–25.
7. PERKENI. Konsensus Pengelolaan dan Pencegahan Diabetes 
Melitus Tipe 2 di Indonesia. Jakarta: Balai Penerbit FK UI 
2006.p.1-2
8. Adams L, Angulo P. Recent concepts in non-alcoholic fatty 
liver disease UK. Diabetic Med 2005;22:1129–33.
9. Dina G, Miriam BV, Elizabeth MB. Non-alcoholic fatty liver 
disease: pathology and pathogenesis. Annu Rev Pathol Mech 
Dis 2010;5:145–71.
10. Dick C, Gerald F, Seng KG, Annette T, Esther MM, Hugh 
RB. Non-alcoholic fatty liver disease as the transducer 
of hepatic oversecretion of very low density lipoprotein 
DISCUSSION
Non-alcoholic fatty liver disease (NAFLD) is 
common, and its prevalence is likely to increase with 
the rising incidence of obesity and diabetes. It is present 
in up to one-third of the general population and in the 
majority of patients with metabolic risk factors, such as 
obesity and diabetes. The associations between obesity 
and fatty liver are well documented.1,8,9
The liver plays a central role in lipid metabolism, 
storing and exporting lipids and lipoproteins. Lipid 
accumulation in the liver is the major hallmark of 
NAFLD. Abnormalities in lipid and lipoprotein 
metabolism accompanied by chronic inflammation 
are considered to be the central pathway for the 
development of several obesity-related co-morbidities, 
such as NAFLD. In NAFLD patients, liver overproduces 
several atherogenic factors, such as cytokines and 
“bad” lipoproteins.4,10
ApoB is the primary apolipoprotein of LDL-c, 
responsible for carrying cholesterol to tissues. ApoB 
is present as a single molecule in low, intermediate, 
and very low density lipoproteins (LDL, IDL and 
VLDL). The clinical interest of this protein lies in the 
fact that it provides a relative accurate estimation of 
circulating LDL.11-14
We used liver ultrasound to detect hepatic fat 
accumulation. The gold standard for fatty liver is 
liver biopsy but liver ultrasound was therefore used 
as an alternative validated method to detect hepatic 
fat accumulation. A positive ultrasound result in 
association with metabolic risk factors is likely to be 
adequate for establishing diagnosis.
Previous Korean study by Seung et al, reported 
that the development of NAFLD was associated 
with elevated measurements of waist circumference, 
fat mass, percentage of body fat and abdominal fat, 
iron, triglycerides, and apoB.1 In another study, from 
Onat et al confirmed that Apo B concentration, which 
Figure 1. Relationship between patient with or without fatty liver 
and apolipoprotein B (apoB) level
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